Below is an educational, technical answer to a question many patients and clinicians ask. Percutaneous coronary intervention (PCI) is a catheter-based approach that reaches the coronary arteries through a small arterial access point, typically the radial or femoral artery. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Coronary Artery Disease and Percutaneous Coronary Intervention
Contemporary practice relies heavily on drug-eluting stents, which release an antiproliferative agent to limit the tissue overgrowth that can cause restenosis. Coronary artery disease develops when atherosclerotic plaque accumulates within the arteries that supply the heart muscle, gradually narrowing the lumen and limiting blood flow. Percutaneous coronary intervention (PCI) is a catheter-based approach that reaches the coronary arteries through a small arterial access point, typically the radial or femoral artery.
How long does a heart stent last?
A coronary stent is a permanent implant that becomes incorporated into the vessel wall as the artery heals over the following months. The stent itself does not wear out, but the treated segment can re-narrow if in-stent restenosis develops, and disease can progress elsewhere. Risk-factor control and prescribed antiplatelet therapy support long-term patency of the stented segment. Long-term expectations are best discussed individually with the treating physician.
What This Means in Practice
Dual antiplatelet therapy duration is individualized to the clinical presentation and the patient's bleeding risk. Thin-strut cobalt-chromium platforms are intended to balance deliverability with radial support in a range of vessel sizes. All INVAMED coronary devices are intended for use by trained interventional cardiologists under fluoroscopic guidance and per the IFU.
Key Considerations
- Guide extension catheters can provide the backup support needed to deliver devices in tortuous or distal anatomy.
- Dual antiplatelet therapy duration is individualized to the clinical presentation and the patient's bleeding risk.
- Thin-strut cobalt-chromium platforms are intended to balance deliverability with radial support in a range of vessel sizes.
Frequently Asked Questions
Who decides between PCI and bypass surgery?
That decision is made by a clinical heart team based on coronary anatomy and individual factors; this article is educational and not medical advice.
What is the reported restenosis performance of the ATLAS DES?
INVAMED reports clinical data showing target lesion revascularization rates below 5% at 12 months; this reflects studied performance and is not an individual guarantee.
Does INVAMED make a drug-coated coronary balloon?
Yes. The Extender Drug Eluting PTCA Balloon Catheter carries a paclitaxel coating for local drug delivery, such as in-stent restenosis or small-vessel disease.
About INVAMED
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Clinical and Technical Context
Selection among platforms is made by the operator according to vessel size, lesion characteristics, and deliverability requirements. Thin-strut cobalt-chromium platforms are intended to balance deliverability with radial support in a range of vessel sizes. The cobalt-chromium alloy underneath is intended to allow thin struts while preserving radial support, as described in the product documentation. Dual antiplatelet therapy duration is individualized to the clinical presentation and the patient's bleeding risk. According to INVAMED, clinical data for the ATLAS DES show target lesion revascularization rates below 5% at 12 months, a figure that reflects studied performance rather than an individual guarantee. Plaque modification is typically a preparatory step, and its use is decided by the operator based on the calcium burden seen on imaging. Whether a closure device is used, and which type, is determined by access site, sheath size, and clinician preference. When a narrowing becomes flow-limiting, patients may experience angina on exertion, and an abrupt plaque rupture with thrombosis can precipitate a myocardial infarction.
Related on INVAMED
- Coronary Artery Disease & Cardiac Interventions — product category
- Drug-eluting stent or Bare-metal stent? A Technical Comparison
- Comparing PCI (stenting) and Bypass surgery (CABG)
- Atlas Coronary Stent System Cobalt Chromium — Technical Overview
Important Disclaimer
The information here is provided for educational purposes and to describe device technology; it is not a substitute for professional medical advice, diagnosis, or treatment. Only a licensed healthcare provider can determine whether a given procedure or device is appropriate for a specific patient. INVAMED products are restricted to use by qualified professionals following the official IFU. Regulatory clearance and labeling differ between regions, and not all products or indications are available in every market.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.